Francesca Lavatelli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6077286/publications.pdf

Version: 2024-02-01

85 papers	3,507 citations	147801 31 h-index	144013 57 g-index
89 all docs	89 docs citations	89 times ranked	2523 citing authors

#	Article	IF	Citations
1	Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood, 2006, 107, 3854-3858.	1.4	266
2	Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine. Clinical Chemistry, 2009, 55, 499-504.	3.2	225
3	The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 2005, 105, 2949-2951.	1.4	207
4	Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood, 2007, 110, 787-788.	1.4	182
5	A practical approach to the diagnosis of systemic amyloidoses. Blood, 2015, 125, 2239-2244.	1.4	156
6	Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood, 2012, 119, 1844-1847.	1.4	155
7	Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica, 2014, 99, 743-750.	3.5	138
8	Amyloidogenic and Associated Proteins in Systemic Amyloidosis Proteome of Adipose Tissue. Molecular and Cellular Proteomics, 2008, 7, 1570-1583.	3.8	134
9	A Caenorhabditis elegansâ€“based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood, 2014, 123, 3543-3552.	1.4	122
10	Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched caseâ€“control study on 174 patients. Leukemia, 2014, 28, 2311-2316.	7.2	113
11	Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient. Nature Communications, 2019, 10, 1269.	12.8	113
12	Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 142-150.	3.0	106
13	Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. Arthritis and Rheumatism, 2009, 61, 1435-1440.	6.7	100
14	Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. American Journal of Hematology, 2012, 87, 465-471.	4.1	95
15	Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Annals of Hematology, 2012, 91, 89-92.	1.8	78
16	Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Annals of Hematology, 2009, 88, 347-350.	1.8	67
17	A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica, 2013, 98, 433-436.	3.5	65
18	In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study. Scientific Reports, 2016, 6, 29096.	3.3	63

#	Article	IF	Citations
19	Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Scientific Reports, 2017, 7, 15661.	3.3	63
20	The workings of the amyloid diseases. Annals of Medicine, 2007, 39, 200-207.	3.8	62
21	Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. FASEB Journal, 2015, 29, 4614-4628.	0.5	60
22	Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Research in Cardiology, 2013, 108, 378.	5.9	56
23	Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis. American Journal of Clinical Nutrition, 2006, 83, 350-354.	4.7	53
24	Proteomic typing of amyloid deposits in systemic amyloidoses. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 177-182.	3.0	50
25	Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity. Scientific Reports, 2017, 7, 16809.	3.3	50
26	AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity. Clinical Lymphoma and Myeloma, 2009, 9, 80-83.	1.4	45
27	Shotgun Protein Profile of Human Adipose Tissue and Its Changes in Relation to Systemic Amyloidoses. Journal of Proteome Research, 2013, 12, 5642-5655.	3.7	45
28	A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2011, 1814, 409-419.	2.3	39
29	Treatment of IgM-Associated AL Amyloidosis With the Combination of Rituximab, Bortezomib, and Dexamethasone. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 143-145.	0.4	36
30	Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. Annals of Hematology, 2012, 91, 399-406.	1.8	35
31	Clinical proteomics for diagnosis and typing of systemic amyloidoses. Proteomics - Clinical Applications, 2013, 7, 136-143.	1.6	33
32	Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1734-1743.	2.3	33
33	Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis. Journal of Biological Chemistry, 2020, 295, 16572-16584.	3.4	32
34	Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 216-221.	3.0	26
35	Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis. Nutrition, 2015, 31, 1228-1234.	2.4	26
36	ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis. Analytical Chemistry, 2019, 91, 2894-2900.	6.5	26

#	Article	IF	Citations
37	Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains. Journal of Molecular Biology, 2020, 432, 845-860.	4.2	26
38	Proteaseâ€sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation. FEBS Journal, 2022, 289, 494-506.	4.7	25
39	Biochemical markers in early diagnosis and management of systemic amyloidoses. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1517-31.	2.3	22
40	A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E. coli. PLoS ONE, 2013, 8, e76022.	2.5	20
41	Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. Journal of Parenteral and Enteral Nutrition, 2014, 38, 891-894.	2.6	19
42	Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 64-66.	3.0	17
43	Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H1158-H1166.	3.2	17
44	Systemic amyloidoses and proteomics: The state of the art. EuPA Open Proteomics, 2016, 11, 4-10.	2.5	16
45	The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis. Clinical Chemistry and Laboratory Medicine, 2016, 54, 939-45.	2.3	15
46	Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy. Blood Cancer Journal, 2020, 10, 90.	6.2	15
47	Age-related amyloidosis outside the brain: A state-of-the-art review. Ageing Research Reviews, 2021, 70, 101388.	10.9	14
48	Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms. Frontiers in Molecular Biosciences, 2022, 9, 830006.	3.5	11
49	An N-glycosylation hotspot in immunoglobulin Îº light chains is associated with AL amyloidosis. Leukemia, 2022, 36, 2076-2085.	7.2	10
50	Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson fromC. elegans. Worm, 2014, 3, e965590.	1.0	9
51	Prognostication of survival and progression to dialysis in AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 136-137.	3.0	9
52	Proteomics in protein misfolding diseases. Clinical Chemistry and Laboratory Medicine, 2009, 47, 627-35.	2.3	8
53	Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 11-13.	3.0	8
54	Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 68-69.	3.0	6

#	Article	IF	Citations
55	Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 64-65.	3.0	6
56	Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing. Proteomics, 2018, 18, e1700353.	2.2	6
57	Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 168-173.	3.0	6
58	Mechanisms of Organ Damage and Novel Treatment Targets in AL Amyloidosis. Hemato, 2022, 3, 47-62.	0.6	6
59	Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 61-63.	3.0	5
60	Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients. Blood, 2019, 134, 320-323.	1.4	5
61	Clinical Amyloid Typing by Proteomics: Performance Evaluation and Data Sharing between Two Centres. Molecules, 2021, 26, 1913.	3.8	5
62	Treatment of AL Amyloidosis with Bortezomib Combined with Alkylating Agents: Results From a Prospective Series of Unselected Patients,. Blood, 2011, 118, 3977-3977.	1.4	5
63	Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 96-97.	3.0	4
64	Advances in proteomic study of cardiac amyloidosis: progress and potential. Expert Review of Proteomics, 2016, 13, 1017-1027.	3.0	4
65	Regulated expression of amyloidogenic immunoglobulin light chains in mice. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 52-53.	3.0	4
66	How do we improve treatments for patients with amyloidosis using proteomics?. Expert Review of Proteomics, 2017, 14, 561-563.	3.0	4
67	Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 105-106.	3.0	4
68	Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 66-67.	3.0	3
69	Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 54-55.	3.0	3
70	Proteomics Fundamentally Advance the Diagnosis and Management of Amyloidosis. Mayo Clinic Proceedings, 2020, 95, 1816-1818.	3.0	3
71	Patterns of relapse after upfront bortezomib therapy in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 60-61.	3.0	2
72	The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 107-108.	3.0	2

#	Article	IF	Citations
73	Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics. Medicina (Lithuania), 2021, 57, 916.	2.0	2
74	PP100-SUN: Nutritional Counseling in Systemic Immunoglobulin Light-Chain (AL) Amyloidosis: A Prospective Randomized, Controlled Trial. Clinical Nutrition, 2014, 33, S56-S57.	5.0	1
75	A Proteomic Approach to the Study of Systemic Amyloidoses. , 2007, , 360-362.		1
76	AMICA: an electronic patient record specifically designed for an amyloidosis network. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 236-238.	3.0	0
77	A workflow management system for the biological samples exchange within the amyloidosis network. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 233-235.	3.0	0
78	Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality. European Heart Journal, 2013, 34, P4239-P4239.	2.2	0
79	Early Harvest Followed by Melphalan-Dexamethasone and Second-Line Autologous Stem Cell Transplantation in AL Amyloidosis.. Blood, 2006, 108, 5449-5449.	1.4	0
80	Prognostic Relevance of Serum N-Terminal Pronatriuretic Peptide Type B and Plasma Bnp in Patients with Al Amyloidosis in Dialysis. , 2007, , 273-274.		0
81	Early Harvest Followed by Melphalan-Dexamethasone and second-Line Autologous Stem Cell Transplantation in Al. , 2007, , 390-392.		0
82	Prolonged Follow-up Study of Al Patients Ineligible for Stem Cell Transplantation Treated with Oral Melphalan and Dexamethasone. , 2007, , 282-282.		0
83	Pathogenesis of Systemic Amyloidoses. , 2010, , 49-64.		0
84	Salvage Therapy with Lenalidomide and Dexamethasone (LDex) In Patients with Advanced AL Amyloidosis Refractory to Both Melphalan and Bortezomib. Blood, 2010, 116, 3062-3062.	1.4	0
85	The Role of Differential Proteomics in Amyloid Typing: The Experience of the Pavia Referral Center. Current Clinical Pathology, 2015, , 323-330.	0.0	0